The aminoglycoside antibiotic neomycin B inhibits
translation in prokaryotes and interferes with RNA–protein
interactions in HIV both in vivo and in vitro. Hitherto,
inhibition of ribozyme catalysis has only been observed
in vitro. We therefore monitored the activity of neomycin
B and several other aminoglycoside antibiotics on splicing
of the T4 phage thymidylate synthase (td) intron
in vivo. All antibiotics tested inhibited splicing, even
chloramphenicol, which does not inhibit splicing in vitro.
Splicing of the td intron in vivo requires translation
for proper folding of the pre-mRNA. In the absence of translation,
two interactions between sequences in the upstream exon
and the 5′ and 3′ splice sites trap the pre-mRNA
in splicing-incompetent conformations. Their disruption
by mutations rendered splicing less dependent on translation
and also less sensitive to neomycin B. Intron splicing
was affected by neither neomycin B nor gentamicin in Escherichia
coli strains carrying antibiotic-resistance genes
that modify the ribosomal RNA. Taken together, this demonstrates
that in vivo splicing of td intron is not directly
inhibited by aminoglycosides, but rather indirectly by
their interference with translation. This was further confirmed
by assaying splicing of the Tetrahymena group
I intron, which is inserted in the E. coli 23
S rRNA and, thus, not translated. Furthermore, neomycin
B, paromomycin, and streptomycin enhanced missplicing in
antibiotic-sensitive strains. Missplicing is caused by
an alternative structural element containing a cryptic
5′ splice site, which serves as a substrate for the
ribozyme. Our results demonstrate that aminoglycoside antibiotics
display different effects on ribozymes in vivo and in vitro.